News
Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback